Evidence map›Paper›PMID 32597565›Full record

Trial reportESC heart failure2020

Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension.

David Fouassier, Anne Blanchard, Antoine Fayol, Guillaume Bobrie, Pierre Boutouyrie, Michel Azizi, Jean-Sébastien Hulot

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

David FouassierCentre d'Investigations Cliniques CIC1418, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Anne BlanchardCentre d'Investigations Cliniques CIC1418, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Antoine FayolCentre d'Investigations Cliniques CIC1418, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Guillaume BobrieAssistance Publique Hôpitaux de Paris, Hypertension unit, Hôpital Européen Georges Pompidou, Paris, France.
Pierre BoutouyrieParis Cardiovascular Research Center PARCC, INSERM, Université de Paris, Paris, France.
Michel AziziCentre d'Investigations Cliniques CIC1418, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Jean-Sébastien HulotCentre d'Investigations Cliniques CIC1418, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Hôpital Européen · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Européen Georges-Pompidou · FRUniversité Paris Cité · FR

Funding

Ministère de la santé (FR) PHRC P040407
6 · The paper itself

Abstract

aimsHypertension is a major contributor to cardiac diastolic dysfunction. Different therapeutics strategies have been proposed to control blood pressure (BP), but their independent impact on cardiac function remains undetermined. In patients with resistant hypertension, we compared the changes in cardiac parameters between two strategies based on sequential nephron blockade (NBD) with a combination of diuretics or sequential renin-angiotensin system blockade (RASB). METHODS AND

resultsAfter a 4-week period where all patients received Irbesartan 300 mg/day + hydrochlorothiazide 12.5 mg/day + amlodipine 5 mg/day, 140 resistant hypertension patients (54.8 ± 11.1 years, 76% men, mean duration with hypertension: 13.1 ± 10.5 years, no previous history of heart failure or current symptoms of congestive heart failure) were randomized 1:1 to the NBD regimen or to the RASB regimen at week 0 (W0, baseline). Treatment intensity was increased at week 4, 8, or 10 if home BP was ≥135/85 mmHg, by sequentially adding 25 mg spironolactone, 20-40 mg furosemide, and 5 mg amiloride (NBD group) or 5-10 mg ramipril and 5-10 mg bisoprolol (RASB group). No other antihypertensive drug was allowed during the study. BP, BNP levels, and echocardiographic parameters were assessed at weeks 0 and 12. The baseline characteristics, laboratory parameters, and plasma hormones (BNP, renin, and aldosterone) and cardiac echocardiographic parameters did not significantly differ between the NBD and the RASB groups. Over 12 weeks, BNP levels significantly decreased in NBD but increased in RASB (mean [CI 95%] change in log-transformed BNP levels: -43% [-67%; -23%] vs. +55% [46%; 62%] in NBD vs. RASB, respectively, P < 0.0001). Similarly, the proportion of patients presenting ≥2 echocardiographic criteria of diastolic dysfunction decreased between baseline and W12 from 31% to 3% in NBD but increased from 19% to 32% in RASB (P = 0.0048). As compared with RASB, NBD induced greater decrease in ambulatory systolic BP (P < 0.0001), pulse pressure (P < 0.0001), and systemic vascular resistance (P < 0.005). In multivariable linear regression analyses, NBD treatment was significantly associated with decreased BNP levels (adjusted ß: -46.41 ± 6.99, P < 0.0001) independent of age, gender, renal function, and changes in BPs or heart rate.

conclusionsIn patients with resistant hypertension, nephron blockade with a combination of diuretics significantly improves cardiac markers of diastolic dysfunction independently of BP lowering.

Indexed as

DiureticsHypertensionAntihypertensive AgentsBlood PressureFemaleHumansMaleNephronsAntihypertensive AgentsDiureticsClinical trialsHeart failurePharmacologyResistant hypertension

Identifiers

PMID32597565
PMCPMC7524081
OpenAlexW3037733732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.